Call Us Contact Us
+44 1494 818 000     Online Enquiry
Lines open
Monday to Thursday
08:30 to 18:00
Friday
08:30 to 17:30
Pharmaceutical | Medical Devices | Scientific | Consumer Healthcare | Dental | Animal Health
Healthcare Communications | Pharmaceutical Executive | Medical Executive | Tech PR | Scientific Executive
         
Latest Jobs
Exclusive vacancies may not be shown here, please contact Daniel on +44 1494 818028 or Daniel@zenopa.com for more information.
Have you registered?
Once you register you can see additional job details, save jobs, track your applications and manage e-lert preferences.

Register now
Daniel Newbury
Recruitment Consultant
Daniel@zenopa.com
+44 1494 818028

Testimonials
In my search for a new position within the pharma industry I found Zenopa's focused and tailored approach to be exactly what I needed to find the job I was looking for.
Brendan, 2011

Quintiles celebrates 30th anniversary

1 March 2012 00:00 in Marketing Services


Quintiles has celebrated the 30th anniversary of its foundation by highlighting some of its achievements over the last three decades.

The biopharmaceutical services provider was established on February 26th 1982 and has since grown into one of the largest organisations of its kind in the world, with more than 25,000 employees and offices in over 60 nations.

All 50 of the world's top-selling pharmaceutical products in 2010 were created using development or commercialisation support from Quintiles, a claim the company has been able to make for at least a decade.

Quintiles chairman and chief executive officer Dr Dennis Gillings noted that the organisation remains actively involved in the development of therapies for conditions such as Alzheimer's, cancer, diabetes, heart disease and infectious disease.

He added: "Even in the earliest days, we recognised that Quintiles could make a difference in people's lives. Today, millions, if not billions of people have been impacted by our work."

Over the last few months, the company has announced several plans to expand further, establishing new commercial services in the Middle East and north Africa, as well as a biomarker-focused research and development business.ADNFCR-8000103-ID-801307012-ADNFCR

Other news stories from 01/03/2012

Related news

Read more in the Zenopa News Archive

How this news is generated

Story collated for Zenopa by the Axonn News Agency



                    
© Copyright 2014 Zenopa Ltd